Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 145

1.

Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients.

Lanigan F, Brien GL, Fan Y, Madden SF, Jerman E, Maratha A, Aloraifi F, Hokamp K, Dunne EJ, Lohan AJ, Flanagan L, Garbe JC, Stampfer MR, Fridberg M, Jirstrom K, Quinn CM, Loftus B, Gallagher WM, Geraghty J, Bracken AP.

FEBS J. 2015 Jun 20. doi: 10.1111/febs.13354. [Epub ahead of print]

PMID:
26094870
2.

Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.

Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, Manzano JL, Fernandez-Figueras MT, Elez E, Muñoz-Couselo E, Botella-Estrada R, Berrocal A, Pontén F, Oord Jv, Gallagher WM, Frederick DT, Flaherty KT, McDermott U, Lorigan P, Marais R, Esteller M.

Nat Med. 2015 Jul;21(7):741-50. doi: 10.1038/nm.3863. Epub 2015 Jun 1.

PMID:
26030178
3.

FKBPL: a marker of good prognosis in breast cancer.

Nelson L, McKeen HD, Marshall A, Mulrane L, Starczynski J, Storr SJ, Lanigan F, Byrne C, Arthur K, Hegarty S, Ali AA, Furlong F, McCarthy HO, Ellis IO, Green AR, Rakha E, Young L, Kunkler I, Thomas J, Jack W, Cameron D, Jirström K, Yakkundi A, McClements L, Martin SG, Gallagher WM, Dunn J, Bartlett J, O'Connor D, Robson T.

Oncotarget. 2015 May 20;6(14):12209-23.

4.

The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.

Szwej E, Devocelle M, Kenny S, Guzik M, O'Connor S, Nikodinovic-Runic J, Radivojevic J, Maslak V, Byrne AT, Gallagher WM, Zulian QR, Zinn M, O'Connor KE.

J Biotechnol. 2015 Jun 20;204:7-12. doi: 10.1016/j.jbiotec.2015.02.036. Epub 2015 Mar 24.

PMID:
25820126
5.

Epidemiologic design and analysis for proteomic studies: a primer on -omic technologies.

Mischak H, Critselis E, Hanash S, Gallagher WM, Vlahou A, Ioannidis JP.

Am J Epidemiol. 2015 May 1;181(9):635-47. doi: 10.1093/aje/kwu462. Epub 2015 Mar 19. Review.

PMID:
25792606
6.

High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients.

van den Hurk K, Balint B, Toomey S, O'Leary PC, Unwin L, Sheahan K, McDermott EW, Murphy I, van den Oord JJ, Rafferty M, FitzGerald DM, Moran J, Cummins R, MacEneaney O, Kay EW, O'Brien CP, Finn SP, Heffron CC, Murphy M, Yela R, Power DG, Regan PJ, McDermott CM, O'Keeffe A, Orosz Z, Donnellan PP, Crown JP, Hennessy BT, Gallagher WM.

Melanoma Res. 2015 Jun;25(3):189-99. doi: 10.1097/CMR.0000000000000149.

PMID:
25746038
7.

Commercialized biomarkers: new horizons in prostate cancer diagnostics.

Murphy L, Prencipe M, Gallagher WM, Watson RW.

Expert Rev Mol Diagn. 2015 Apr;15(4):491-503. doi: 10.1586/14737159.2015.1011622. Epub 2015 Feb 24.

PMID:
25711191
8.

p53 as a target for the treatment of cancer.

Duffy MJ, Synnott NC, McGowan PM, Crown J, O'Connor D, Gallagher WM.

Cancer Treat Rev. 2014 Dec;40(10):1153-60. doi: 10.1016/j.ctrv.2014.10.004. Review.

PMID:
25455730
9.

Interrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.

Jarzabek MA, Amberger-Murphy V, Callanan JJ, Gao C, Zagozdzon AM, Shiels L, Wang J, Ligon KL, Rich BE, Dicker P, Gallagher WM, Prehn JH, Byrne AT.

Br J Cancer. 2014 Dec 9;111(12):2275-86. doi: 10.1038/bjc.2014.529. Epub 2014 Nov 6.

PMID:
25375271
10.

OvMark: a user-friendly system for the identification of prognostic biomarkers in publically available ovarian cancer gene expression datasets.

Madden SF, Clarke C, Stordal B, Carey MS, Broaddus R, Gallagher WM, Crown J, Mills GB, Hennessy BT.

Mol Cancer. 2014 Oct 24;13:241. doi: 10.1186/1476-4598-13-241.

11.

Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer.

O'Leary PC, Terrile M, Bajor M, Gaj P, Hennessy BT, Mills GB, Zagozdzon A, O'Connor DP, Brennan DJ, Connor K, Li J, Gonzalez-Angulo AM, Sun HD, Pu JX, Pontén F, Uhlén M, Jirström K, Nowis DA, Crown JP, Zagozdzon R, Gallagher WM.

Breast Cancer Res. 2014 Jul 10;16(4):R79. doi: 10.1186/bcr3691.

12.

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.

Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine JC, Berx G.

Cell Death Differ. 2014 Aug;21(8):1250-61. doi: 10.1038/cdd.2014.44. Epub 2014 Apr 25.

13.

Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers.

O'Hurley G, Sjöstedt E, Rahman A, Li B, Kampf C, Pontén F, Gallagher WM, Lindskog C.

Mol Oncol. 2014 Jun;8(4):783-98. doi: 10.1016/j.molonc.2014.03.008. Epub 2014 Mar 21. Review.

14.

microRNAs: a new class of breast cancer biomarkers.

Mulrane L, Klinger R, McGee SF, Gallagher WM, O'Connor DP.

Expert Rev Mol Diagn. 2014 Apr;14(3):347-63. doi: 10.1586/14737159.2014.901153. Review.

PMID:
24649821
15.

A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer.

Mulrane L, Gallagher WM, O'Connor DP.

Breast Cancer Res. 2014 Nov 18;16(6):467. doi: 10.1186/s13058-014-0467-x.

16.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

17.

MetSizeR: selecting the optimal sample size for metabolomic studies using an analysis based approach.

Nyamundanda G, Gormley IC, Fan Y, Gallagher WM, Brennan L.

BMC Bioinformatics. 2013 Nov 21;14:338. doi: 10.1186/1471-2105-14-338.

18.

The analysis of serum response factor expression in bone and soft tissue prostate cancer metastases.

O'Hurley G, Prencipe M, Lundon D, O'Neill A, Boyce S, O'Grady A, Gallagher WM, Morrissey C, Kay EW, Watson RW.

Prostate. 2014 Feb;74(3):306-13. doi: 10.1002/pros.22752.

PMID:
24249383
19.

miRNA dysregulation in breast cancer.

Mulrane L, McGee SF, Gallagher WM, O'Connor DP.

Cancer Res. 2013 Nov 15;73(22):6554-62. doi: 10.1158/0008-5472.CAN-13-1841. Epub 2013 Nov 7. Review.

20.

Investigation of molecular alterations of AKT-3 in triple-negative breast cancer.

O'Hurley G, Daly E, O'Grady A, Cummins R, Quinn C, Flanagan L, Pierce A, Fan Y, Lynn MA, Rafferty M, Fitzgerald D, Pontén F, Duffy MJ, Jirström K, Kay EW, Gallagher WM.

Histopathology. 2014 Apr;64(5):660-70. doi: 10.1111/his.12313. Epub 2013 Dec 12.

PMID:
24138071
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk